Answers are grounded in this paper and cite their sources.
Baseline anemia is a known negative prognostic feature in myelofibrosis (MF), possibly contrary to ruxolitinib (RUX)-induced anemia. On the other hand, transfusion dependence (TD) has a detrimental impact that is irrespective of treatment status. The lack of consistency among definitions of TD and anemia response in MF has, however, partially hampered trial result interpretation and inter-study comparisons. In August 2024, Blood has released the Revised International Working Group-European LeukemiaNet (IWG-ELN) criteria for anemia response in MF, redefining both baseline anemia and its response to treatment. The criteria have been formulated by an international group of experts on the basis of available data in MF, adopting some myelodysplastic syndromes-specific features [1]. Inherent to their nature, not all aspects of the revised criteria, especially with respect to the number of transfusions necessary to define TD anemia (TDA) and the fine-grained characterization of anemia response, have been formally tested for their prognostic value. We thus set out to apply the updated criteria within the ambispective observational RUXOREL-MF study (NCT03959371) to establish the impact on survival of the new definition of TDA and non-TDA and, second, to assess early anemia response in RUX-treated MF patients. The RUXOREL-MF study focuses on RUX-treated MF patients within an extensive hematology network, as already described [2]. The study was approved by the Review Board of each institution and conducted in accordance with the Declaration of Helsinki. The study database comprises 288 patients regularly followed at 17 centers. In-depth information regarding the number of transfused units and corresponding dates is available, in order to correctly apply the revised IWG-ELN criteria. Given the prognostic relevance of early modifications of transfusion status under RUX [2], we decided to focus the anemia response part of the analysis on the first 6 months of treatment. Patient selection criteria for enrollment in our analysis were as previously defined [2], resulting in a cohort of 209 patients. Four patients, however, lacked baseline transfusion status and were excluded. The revised IWG-ELN criteria proposed three strata for anemia definition, and we applied them to the RUXOREL-MF cohort. A hemoglobin (Hgb) level of < 10 g/dL, irrespective of gender, is considered a suitable key inclusion criterion for clinical trials targeting anemia in MF. TDA is defined as the need for ≥ 3 units of red blood cells/12 weeks. Non-TDA includes anemic subjects who do not qualify for TDA. Responses are graded into “major” and “minor” and are separate for TDA and non-TDA. Major responses require the absence of transfusions for 12 weeks and a rolling 12-week average Hgb increase of ≥ 1.5 g/dL from pretreatment baseline. Minor responses comprise a ≥ 50% reduction in transfusions in TDA and a rolling 12-week average Hgb increase of ≥ 1.0 g/dL (but < 1.5 g/dL) from pretreatment baseline in non-TDA. Progressive anemia, on the other hand, includes a ≥ 50% increase in transfusion burden in TDA and, in non-TDA, either meeting criteria for TDA or a decrease in Hgb by > 1.5 g/dL. Patients who do not meet criteria for response or progression are termed “stable.” Mean (standard deviation) age of the 205 patients included in the current analysis was 65.2 (9.7) years and most were male (n = 130). Eighty-three (40.5%) out of 205 patients had anemia at RUX start, of whom 33 (16.1%) were TD and 50 (24.4%) were not. When considering RUX starting doses, 120 (58.5%) patients were treated per label, 75 (36.6%) at a lower dose, and 10 (4.9%) at a higher dose. We first examined the clinical relevance of the three strata of anemia definition at RUX start. We found significant differences in terms of survival among the three conditions (p = 0.0011, Figure 1A). In fact, median overall survival was 83.2 months (range, 67.2-NA) for non-anemic patients, 49.2 months (range, 40.3–NA) for those with non-TDA, and 41.3 months (range, 30.2–NA) for those with TDA. When comparing the three conditions, the hazard ratio, using the non-anemic population as a reference, was 1.6 (95% confidence interval, 95% CI, 0.9–2.9) for non-TDA and 2.8 (95% CI 1.6–5.1) for TDA. This information is critical and establishes the robustness of the revised IWG-ELN definition of TDA and non-TDA at RUX start by providing evidence to support its differential impact on patient survival in the setting of contemporary treatment with RUX. In addition, in line with the required 12-week observation period, we assessed responses in anemic patients after 3 and 6 months of RUX treatment (Figure 1B). As expected, a reduced proportion of patients qualified for a positive anemia response at the 3- and 6-month time points in both the TDA and non-TDA subgroups. Interestingly, however, approximately one fourth of TDA patients experienced a ≥ 50% reduction in transfusion burden at both time points when compared with pre-RUX transfusion requirements. Anemia progression was more frequent in non-TDA as opposed to TDA, likely because of the differences in the definition of progression within the two subgroups. To progress, non-TDA patients need to experience a > 1.5 g/dL Hgb decrease from baseline, which is relatively common under RUX, or to become TD, whereas, on the other hand, TDA patients undergo progression if their transfusion need increases quite considerably (i.e., ≥ 50%). Conversely, anemia stability is more frequent in TDA than in non-TDA patients. Logistic regression evaluating the probability of obtaining an anemia response (grouping major and minor responses) according to RUX starting doses (per label or lower) showed that lowering RUX starting doses did not seem to result in anemia improvement (3 months odds ratio, OR, 0.75, 95% CI 0.20–2.83, p = 0.68; 6 months OR 0.44, 95% CI 0.13–1.54, p = 0.20), nor did it reduce the rates of anemia progression (3 months OR 0.8, 95% CI 0.3–2.1, p = 0.67; 6 months OR 1.2, 95% CI 0.5–3.1, p = 0.65). Ten baseline anemic patients received concomitant treatments with the aim of improving anemia, among whom only one received luspatercept therapy, six received erythropoiesis-stimulating agents (ESAs), and three received danazol. One patient on ESA and one on danazol obtained a major and a minor anemia response, respectively. All other patients either had progressive anemia (the majority, i.e., seven at the 3-month time-point and six at the 6-month time-point) or anemia stability. Lastly, when examining survival probabilities, we could not detect significant differences among distinct anemia responses, likely due to the small number of responders. Given the existence of multiple prognostic determinants other than anemia, we performed the same analysis considering only the 62 anemic patients with higher prognostic scores (e.g., intermediate-2/high risk per Dynamic International Prognostic Scoring System in primary MF and per MYSEC Prognostic Model in secondary MF), and still could not dissect patient outcomes according to different anemia responses, albeit having thus further reduced patient numbers. To our knowledge, this analysis provides the first evidence of the applicability of the revised IWG-ELN criteria in the setting of RUX-treated MF patients outside of clinical trials. The characteristics of our patient population, comprised of approximately 40% and 16% anemic and TD patients at RUX start respectively, underscore the proportion of MF patients for whom harmonizing anemia outcomes is particularly relevant. The newly proposed three strata thresholds defining absence of anemia, non-TDA, and TDA capture the progressively detrimental effect of the three conditions in our contemporary cohort and are thus prognostically relevant. In line with RUX's on-target effect, anemia responses in our cohort are infrequent. We found that anemia response is not increased, nor is anemia progression reduced in patients who start with lower RUX doses with respect to those allowed per label according to their platelet count. This underlines the notion, already emerged from our RR6 and other analyses, that exceedingly low RUX starting doses are in general not beneficial for patients. Several drugs in the MF treatment scenario, some of which are still under investigation, yield significant anemia responses, albeit defined according to trial-specific criteria, either as single or add-on agents. Approximately one third of TD patients on RUX who are treated with add-on luspatercept become transfusion-independent (TI) during the entire treatment period, and one out of two reaches a 50% reduction in transfusion need [3]. Other anti-anemia drugs, given as single agents or in combination with RUX, such as elritercept, an inhibitor of select TGF-beta superfamily ligands, including activin [4], and DISC-0974, a monoclonal antibody binding hemojuvelin and blocking BMP signaling [5], are under investigation and preliminary results are available. When collectively analyzing available momelotinib trial data, the rate of TI at Week 24 ranges from 31% (JAK inhibitor-exposed, Momentum study) to 67% (JAK inhibitor-naïve, Simplify-1 study) [6]. In the Persist-2 trial, pacritinib determines a 24% rate of TI at Week 24 among non-TI patients at baseline [6]. It will therefore be of great interest to test the prognostic impact of different anemia responses, defined according to the revised IWG-ELN, in patients treated with anemia-directed strategies. M.M. and F.P. contributed to the conception and design of the work and wrote the paper. L.B. performed the statistical analysis. M.M., B.M., A.I., E.M.E., M.C.F., M.F., E.R., M.Ca., M.C.C., M.D., A.M., E.M., F.L., A.V., M.U., M.C.D.C., M.A., D.C., M.G.D.P., M.Co., and F.P. contributed data collection. B.M., A.I., E.M.E., M.C.F., M.F., E.R., M.Ca., M.C.C., M.D., A.M., E.M., F.L., A.V., M.U., M.C.D.C., M.A., D.C., M.G.D.P., and M.Co. contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript. A.I. received speaker honoraria from Novartis, Pfizer, Incyte, BMS, Celgene. E.R. received consultancy fees from Novartis. M.Co. is an advisory board participant for Abbvie, Astrazeneca, Beigene, GSK, Johnson & Johnson; received speaker honoraria from Abbvie, Astrazeneca; received research funding from Abbvie, GSK, Johnson & Johnson, and Karyopharm Therapeutics. F.P. received speaker honoraria from Novartis, Celgene, BMS, Janssen; is an advisory board participant for Celgene, Novartis, Roche, Janssen, Abbvie, Karyopharm Therapeutics. The other authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Maffioli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: